Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor The study by Dr Chung and colleagues1 identified CYP2C variants, which participate in drug clearance,2 as important genetic factors associated with phenytoin-related severe cutaneous adverse reactions. Nevertheless, their analysis did not take into account the potential influence of coadministered drugs. For this reason, I would like to comment on the importance of drug interactions in pharmacogenetic studies, which are designed to examine the influence of certain genetic variants on drug pharmacokinetics (eg, pharmacological and/or toxic dose-dependent activity).
Lozano R. Genetic Factors Associated With Severe Cutaneous Adverse Reactions. JAMA. 2014;312(20):2165–2166. doi:10.1001/jama.2014.14145
Customize your JAMA Network experience by selecting one or more topics from the list below.